BCL2 and lymphoplasmacytic lymphoma: These mechanisms (i.e., BCL2 gains, TP53 aberrations, and 13q14.2 deletions) contribute to BCL2 protein overexpression in virtually all MCL and lymphoplasmacytic lymphomas.